Sweden: Christer Nordstedt to take up CEO role at Oblique Therapeutics

Oblique Therapeutics, a biotechnology company focused on new antibody medicines for severe diseases, has announced Christer Nordstedt as CEO. Nordstedt will assume the position on December 1, 2022. Nordstedt has broad and international experience within the pharmaceutical industry from operational and strategic positions at management level in companies like Vivesto, Teva Pharmaceuticals, Orion Corporation, Eli…

You must be a HMI Subscriber to view this content.

Subscribe Now »